Neumora Therapeutics, Financials
| NMRA Stock | 9.80 0.14 1.41% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.0058 | 0.0065 |
|
| |||||
| Current Ratio | 20.34 | 19.0466 |
|
|
The essential information of the day-to-day investment outlook for Neumora Therapeutics, includes many different criteria found on its balance sheet. An individual investor should monitor Neumora Therapeutics,'s cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Neumora Therapeutics,.
Net Income |
|
Neumora | Select Account or Indicator |
Please note, the presentation of Neumora Therapeutics,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neumora Therapeutics,'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Neumora Therapeutics,'s management manipulating its earnings.
Neumora Therapeutics, Stock Summary
Neumora Therapeutics, competes with SunOpta, GMS, Olympic Steel, Aspen Insurance, and Hanover Insurance. Neumora Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 640979100 |
| Location | Massachusetts; U.S.A |
| Business Address | 490 Arsenal Way, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.neumoratx.com |
| Phone | 857 760 0900 |
Neumora Therapeutics, Key Financial Ratios
| Return On Equity | -0.77 | ||||
| EBITDA | (187.53 M) | ||||
| Net Income | (235.93 M) | ||||
| Book Value Per Share | 2.38 X | ||||
| Market Capitalization | 1.61 B |
Neumora Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neumora Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Neumora Therapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neumora Therapeutics, competition to find correlations between indicators driving Neumora Therapeutics,'s intrinsic value. More Info.Neumora Therapeutics, Common is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At present, Neumora Therapeutics,'s Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neumora Therapeutics,'s earnings, one of the primary drivers of an investment's value.Neumora Therapeutics, Systematic Risk
Neumora Therapeutics,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Neumora Therapeutics, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on Neumora Therapeutics, correlated with the market. If Beta is less than 0 Neumora Therapeutics, generally moves in the opposite direction as compared to the market. If Neumora Therapeutics, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Neumora Therapeutics, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Neumora Therapeutics, is generally in the same direction as the market. If Beta > 1 Neumora Therapeutics, moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Neumora Therapeutics, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Neumora Therapeutics,'s growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Neumora Therapeutics, growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Neumora Therapeutics, December 3, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Neumora Therapeutics, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Neumora Therapeutics, Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of Neumora Therapeutics, Common based on widely used predictive technical indicators. In general, we focus on analyzing Neumora Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neumora Therapeutics,'s daily price indicators and compare them against related drivers.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 26.16 | |||
| Value At Risk | (7.27) | |||
| Potential Upside | 7.62 |
Complementary Tools for Neumora Stock analysis
When running Neumora Therapeutics,'s price analysis, check to measure Neumora Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neumora Therapeutics, is operating at the current time. Most of Neumora Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Neumora Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neumora Therapeutics,'s price. Additionally, you may evaluate how the addition of Neumora Therapeutics, to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |